Results: At a median follow-up of 61 months, 2 LR patients (1.2%) and 2 IR patients (1.5%) experienced grade 3 GU toxicities, far below the 10% toxicity rate deemed excessive (upper limits of 95% confidence interval, 3.5% and 4.3%, respectively). No grade 4 or 5 toxicities occurred. All grade 3 toxicities were GU, occurring 11 to 51 months after treatment. For the entire group, the actuarial 5-year overall survival rate was 95.6% and the DFS rate was 97.1%. The 5-year DFS rate was 97.3% for LR patients (superior to the 93% DFS rate for historical controls; P = .0008; lower limit of 95% confidence interval, 94.6%) and 97.1% for IR patients.
Conclusion: Dose-escalated prostate SBRT was administered with minimal toxicity in this multi-institutional study. Relapse rates compared favorably with historical controls. SBRT is a suitable option for LR and IR prostate cancer.
Authors: Robert M. Meier, MD, Daniel A. Bloch, PhD, Cristian Cotrutz, PhD, Alan C. Beckman, MD, George T. Henning, MD, Shermian A. Woodhouse, MD, Shirnett K. Williamson, MD, Najeeb Mohideen, MD, John J. Dombrowski, MD, Robert L. Hong, MD, David G. Brachman, MD, Patrick W. Linson, MD, Irving D. Kaplan, MD
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints Meier, Robert M. et al. International Journal of Radiation Oncology • Biology • Physics, Volume 102, Issue 2, 296 - 303
Supported by Accuray and the Swedish Cancer Institute Foundation.
This protocol is registered with ClinicalTrials.gov (identifier NCT00643994).